Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck

Japanese Journal of Clinical Oncology

Volumn 42, Issue 10, 2012, Pages 927-933

  Kiyota, Naomi ^a   Tahara, Makoto ^b   Okano, Susumu ^b   Kawashima, Mitsuhiko ^b   Matsuura, Kazuto ^c   Onozawa, Yuske ^d   Nibu, Kenichi ^a   Hayashi, Ryuichi ^b   Yoshimura, Kenichi ^e   Ohtsu, Atsushi ^b  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c Miyagi Cancer Center   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adjuvant chemoradiotherapy; Cisplatin; Head and neck cancer; Post operative high risk patients

Indexed keywords

CISPLATIN; DEXAMETHASONE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; BONE NECROSIS; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CERVICAL LYMPH NODE; CLINICAL ARTICLE; DERMATITIS; DISTANT METASTASIS; DRUG SAFETY; DYSPHAGIA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEARING IMPAIRMENT; HUMAN; HYPOPHARYNX CARCINOMA; HYPOTHYROIDISM; INFECTION; JAPANESE; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; MOUTH CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POPULATION; POSTOPERATIVE CARE; RADIATION DOSE; RECURRENCE FREE SURVIVAL; SIDE EFFECT; TASTE; THROMBOCYTOPENIA; TOTAL PARENTERAL NUTRITION; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84866748635     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys128     Document Type: Article

References (21)

1. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New Engl J Med 2004;350:1937-44.
2. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. New Engl J Med 2004;350:1945-52.
3. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27:843-50.
4. Al-Sarraf M, Pajak TF, Byhardt RW, Beitler JJ, Salter MM, Cooper JS. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 1997;37:777-82.
5. Kaplan E, Meter P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
6. Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiation therapy in high-risk head and neck squamous cell carcinoma. Cancer 2009;115:2464-71.
7. Isobe K, Kawakami H, Uno T, et al. Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: is intergroup study 0099 feasible in Japanese patients? Jpn J Clin Oncol 2003;33:497-500.
8. Nishimura G, Tsukuda M, Horiuchi C, et al. Decrease of creatinine clearance rate with aging in patients with head and neck cancer in Japan. Int J Clin Oncol/Jpn Soc Clin Oncol 2007;12:120-4.
9. Zenda S, Onozawa Y, Tahara M, et al. Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results. Jpn J Clin Oncol 2007;37:725-9.
10. Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol 2004;22:4657-9.
11. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22: 4665-73.
12. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-64.
13. Rampino M, Ricardi U, Munoz F, et al. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial. Clin Oncol (R Coll Radiol) 2011;23:134-40.
14. Otty Z, Skinner MB, Dass J, et al. Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients. Asia Pac J Clin Oncol 2011;7:287-92.
15. Porceddu SV, Campbell B, Rischin D, et al. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004;60:365-73.
16. Bachaud J, Cohen-Jonathan E, Alzieu C. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999-1004.
17. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys 1997;39:137-48.
18. Dinshaw KA, Agarwal JP, Laskar SG, Gupta T, Shrivastava SK, Cruz AD. Head and neck squamous cell carcinoma: the role of post-operative adjuvant radiotherapy. J Surg Oncol 2005;91:48-55.
19. Peters L, Helmuth G, Ang K. Evaluation of the dose for postoperative radiation therapy of head and neck cancer. Int J Radiat Oncol Biol Phys 1993;26:3-11.
20. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004;101:2222-9.
21. Ang K, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome. J Clin Oncol 2010;28:15s, abstr.5507.